As pressure to cut health-care costs builds, the imperative to demonstrate "value" has become central. Even as promising new therapies for deadly and debilitating diseases - cancer, cystic fibrosis and hepatitis C, to name a few - receive FDA approval and come to market, there is no guarantee the patients who need them will be reimbursed. They are left to worry whether these innovations will be economically out of reach, while the companies that produce them scramble to prove their value. What happens when value is calculated without patients' input? At this event, we'll hear from patients, drug developers, payers and providers, who'll discuss how reimbursement criteria impede or accelerate the advances that extend and improve lives.